ACCORDING to the hypothesis that locally produced adenosine is an important physiological regulator of coronary vascular resistance in mammalian hearts (Berne, 1963) , adenosine is produced by cardiac cells in proportion to their oxygen demand and initiates relaxation of coronary vascular smooth muscle, thereby increasing local blood flow and oxygen delivery. The adenosine concentration in the vicinity of the coronary resistance vessels is thought to be the resultant of the rate of synthesis mediated by 5'-nucleotidase (Rubio et al., 1973) , opposed primarily by transport back into the cardiac cell and incorporation into its nucleotide pool (Olsson, et al., 1972) and, to a smaller extent, by degradation of adenosine and washout of these products into the coronary venous effluent (Rubio et al., 1969; Snow et al., 1973) .
The existence of a coronary adenosine receptor is a central feature of this hypothesis. Although such a receptor has not been isolated, the receptor concept is supported by evidence that coronary vasoactivity is a property of many purine nucleosides and that the coronary effects of adenosine are antagonized by methylxanthines (Afonso, 1970) . The demonstration that adenosine and theophylline covalently linked to polymers too large to penetrate into cells nevertheless closely mimic the effect of the parent purines Schrader et al., 1977) suggests that this receptor may lie on the surface of the coronary myocyte.
This evidence favoring the adenosine hypothesis is opposed by uncertainty as to whether the coronary vasoactivity of adenosine is such that the amounts present in heart muscle, usually one to several nmol/g wet weight (Olsson, 1970; Berne et al., 1971) , can in fact produce the coronary flow changes observed during physiological responses. Experiments employing intracoronary adenosine infusions in open-chest dogs suggest that the effective concentration of adenosine may range between a low value of 0.1 IXM to as high as 0.1 mM (Wolf and Berne, 1956; Rubio et al., 1969; Moir and Downs, 1972; Olsson et al., 1978) .
Further, the evidence suggesting that adenosine and its congeners act directly on a vascular receptor is ambiquous, because several adenosine analogs exhibiting coronary vasoactivity also inhibit the cellular uptake of adenosine , thus raising the possibility that they act secondarily by increasing the concentration of endogenous adenosine in the interstitial space rather than by directly interacting with an adenosine receptor. Indeed, available evidence suggests that the purine 6-amino group and the C-2' and C-3' ribose hydroxyls are determinants of binding common to both the adenosine receptor and the adenosine transport system .
This report concerns studies aimed at resolving some of these ambiguities. The coronary vasoactivities of adenosine and a number of its analogs were compared in conscious, instrumented dogs to obtain data as free as possible from the effects of anesthesia, surgical trauma, and blood gas abnormalities associated with acute animal preparations. These ADENOSINE CORONARY VASOACTIVITY/Olssonetal. 469 analogs were chosen to assess in as much detail as possible the contribution of each steric and chemical feature of the adenosine molecule to its coronary vasoactivity. To define the relationship between the results obtained in conscious dogs in the present study with published results obtained in acute preparations, the coronary vasoactivity of a limited number of analogs was compared directly in both types of preparation. The Quantitative StructureActivity Relationship (QSAR) technique (Hansch, 1969) applied to the combined data identified some of the factors governing the vasoactivity of adenosine.
Methods
The sources and structural formulas of the analogs used in this study are given in Table 1 and Figure 1 .
Healthy dogs weighing 25 kg or more were trained preoperatively to lie quietly without restraint on a padded table in a quiet room. During thoracotomy under pentobarbital anesthesia (approximately 25 mg/kg, iv), an electromagnetic flowmeter and occlusive cuff were placed around the circumflex branch of the left coronary artery. A Silastic catheter was placed in the coronary artery (Elliot et al., 1968) for drug infusion, and a second catheter was placed in the aortic root for blood pressure measurement.
The experiments began when postsurgical convalescence was complete, as judged by the dog's normal activity and hematocrit, and a resting heart rate of 45-60/min. A typical experimental run consisted of recordings of phasic blood pressure and coronary flow, which included two coronary occluc6 NHj, NHj sions of sufficient length (usually 15-20 seconds) to cause maximum coronary vasodilation. After an interval of 10 minutes for recovery, a solution of nucleoside was infused into the coronary artery from a Harvard infusion pump and calibrated syringe until coronary flow was stable at a new level for >30 seconds, whereupon records of coronary flow and perfusion pressure, including a brief coronary flow zero, were obtained. The rate of nucleoside infusion was increased and recordings repeated when coronary flow stabilized. A total of five or six infusions over a 50-to 100-fold range of delivery rates constituted each experimental run. At the end of each run, the dog was returned to his cage. Up to four nucleosides were tested each day, with a minimum of 2 hours between each test. If there appeared to be residual heart rate or coronary flow effects from the previously administered nucleoside, testing was stopped until the following day.
The dogs used in the acute studies were anesthetized either with pentobarbital, iv, or with 1% halothane inhalation following induction by surital, iv. Blood gas values were monitored closely and ventilation was adjusted to maintain arterial P02 above 90 mm Hg, PCO2 between 35 and 45 mm Hg, and pH between 7.35 and 7.45. The left coronary artery was perfused with blood from the left carotid artery via a Gregg cannula. The protocols for evaluating the analogs were similar to those for the studies in conscious dogs, except that the interval between the administration of different nucleosides was reduced to 30 minutes.
The experimental design called for the administration of each nucleoside twice to each of two conscious dogs and once to each of two of the anesthetized dogs. The order of nucleoside administration was randomized by drawing lots. The coronary hemodynamic responses to a series of adenosine infusions was tested at least weekly in each of the conscious dogs and at the beginning and end of each experiment in the anesthetized dogs.
Data Analysis
Data recorded from the conscious dogs included mean and phasic coronary blood flow rate and aortic pressure. Because these dogs exhibited the marked sinus arrythmia characteristic of their state of health and training, mean stroke coronary flow rate, blood pressure, and consequently, coronary conductance varied somewhat from beat to beat. To minimize this variation, late diastolic coronary conductance (LDCC) was used as an index of coronary vascular tone (Dennison and Green, 1958) . Data on coronary flow rate and blood pressure measured at a point just prior to the transient late diastolic coronary flow reduction due to atrial systole from 10 to 12 beats (two to three complete respiratory cycles) were used to calculate mean LDCC (Fig. 2) . Changes in LDCC (ALDCC) were expressed as a fraction of the difference between LDCC at maximum coronary vasodilation (peak reactive hyperemia) and basal LDCC by the formula ALDCC = (LDCC -LDCC o )/(LDCC ma * -LDCC O ), in which the subscripts max and o refer, respectively, to the peak reactive hyperemia and basal states. The estimated concentration of nucleoside in coronary plasma water was calculated from the rate of nucleoside infusion (mol/min) and mean coronary plasma flow rate (liters/min) as previously described (Olsson et al., 1972) .
The concentration of nucleoside causing halfmaximal coronary vasodilation (EDM) was estimated by log-logit transformation of the ALDCC and [nucleoside] data; i.e., by solving the linear regression of logit [ALDCC] on log [nucleoside] for ALDCC = 0.5. To facilitate dog-to dog comparisons, the relative potency of each nucleoside was compared to that of adenosine by calculating the molar potency ratio (MPR), the EDM of adenosine in that dog divided by the ED50 of the nucleoside.
Quantitative Structure-Activity Relationships (QSAR):
Data on the electronic and steric parameters of various substituents were obtained from Brown and VOL. 45, No. 4, OCTOBER 1979 Okamoto (1958) and Hansch et al. (1973) . The 2-butanol:water distribution coefficient provided an estimate of the hydrophobic parameter. This was estimated by dissolving the nucleosides in butanol that had been saturated with 0.1 M KHPO 4 , pH 7.4. The concentration of nucleoside in this solution was adjusted to give an absorbance of approximately 2 at an absorption maximum characteristic of that nucleoside. This solution then was shaken with an equal volume of KHPO^, pH 7.4, previously saturated with 2-butanol. The two phases were separated by centrifugation and the absorbance of each phase was estimated. The experiment was repeated if the decrease in absorbance in the butanol phase did not agree with the increase in absorbance in the KHPO* phase within 3%. The partition coefficient was calculated as the ratio of absorbance of the butanol phase divided by that of the aqueous phase.
The QSAR approach assumes that potency is related to its determinants by the equation, log MPR = a log P + bo + cS + d, where P is a hydrophobicity term (in this study, the 2-butanol: water coefficient), a is a electronic term, S a steric term, and a, b, c, and d are constants. The electronic parameter can be further factored into resonance (R) and inductance (I) terms, which are additive. The contribution of each parameter to vasoactivity was evaluated by linear regression and multiple partial correlation techniques.
Results

Coronary Vasoactivity of Adenosine
Figure 2 is taken from the record of a typical experiment in a conscious dog and illustrates the coronary vasoactivity of adenosine as well as the method of estimating LDCC. In every dog, adenosine increased LDCC to the same level as that attained at the peak of a reactive hyperemic response that caused maximum coronary flow. The ED50 of adenosine in the conscious dogs ranged between 0.35 and 2.0 jiM; in five of the six dogs, these values were 0.78 JXM or less and averaged 0.57 ± 0.18 (SD) JUM. The atypically high ED50 of 2.0 jtM in one dog is unexplained. The coronary flow rates and molar potency ratios of the test nucleosides in this animal were comparable to those of the other five dogs. In the eight open-chest dogs, the ED50 of adenosine was significantly higher than that of the conscious animals, averaging 1.01 ± 0.25 fiM (0.02 > P > 0.01; <-test for unpaired samples of unequal size, 11 degrees of freedom. The dog having an ED50 for adenosine of 2 fiM was excluded from this comparison.) The within-animal variation in adenosine ED50 of the conscious animals over the 29 days of the study (range, 23-38 days) has a coefficient of variation of 9%. Changes in the ED50 of adenosine were not dependent on the duration of the study.
The comparability of the molar potency ratios estimated in conscious and anesthetized dogs was evaluated with seven nucleosides, each of which was administered to each of two conscious and to two or three of eight open-chest dogs. Figure 3 shows that the potency of each nucleoside, relative to the potency of adenosine, is closely similar in the two types of experimental preparation. of bases and nucleosides was chosen to test, to the extent possible, the steric and chemical features of the adenosine molecole that might contribute to its affinity for the putative coronary adenosine receptor. This analysis proceeds from a generalized model of the adenosine receptor which consists of separate purine-and ribose-binding domains whose spatial relationship to each other is determined by the glycosylic torsion angle (Fig. 4) . The possible chemical determinants of binding to each domain include: the pyrimidine and imidazole rings, the substituents on the purine base, and the hydroxyls of the ribose. To examine these factors, the test nucleosides usually differed from adenosine in only one chemical feature; a limited number of doubly modified purine ribosides have been included in order to examine possible interactions between substituents.
Coronary Vasoactivity of Adenosine Analogs
Purine Bases
The three purine bases tested (compounds 2-4) were devoid of coronary vasoactivity. Although not tested in this study, it is also well known that ribose itself has no coronary vasoactivity, indicating that the vasoactivity of a nucleoside is absolutely dependent on both the base and ribose moieties. It is important to recognize that lack of vasoactivity does not mean that a purine base cannot bind to the receptor; the antagonism of adenosine vasodilation by theophylline is clear evidence of this.
Neither cytidine nor aminoimidazolecarboxamide riboside was active, indicating that neither the pyrimidine nor imidazole ring by itself is able to confer vasoactivity. Generally, isosteric (C «=* N) substitutions (compounds 38-41) reduced but did not abolish activity; such substitutions in the pyrimidine ring seem better tolerated than those in the imidazole moiety. Displacement of the glycosylic bond from N-9 to N-3 (3-isoadenosine) had a relatively minor effect on coronary vasoactivity. However, extension of the purine base by 2.4 A (linbenzoadenosine) or the addition of an additional imidazole ring (7V-l,6-ethenoadenosine) completely abolished activity. These results suggest that the purine binding site cannot accommodate bases much larger than adenine. The substantial activity of 3-isoadenosine, in which the respective relationships of the pyrimidine and imidazole moieties to ribose is reversed, and that of the ribosides of adenine isosteres suggests that, in addition to these dimensional constraints, electronic factors have an important influence on binding affinity.
Purine Substituents
Substituents at N-l, C-6, and C-8 reduced or abolished coronary vasoactivity, whereas certain substitutions at C-2 greatly enhanced affinity for the adenosine receptor. The potency of the three ribosides substituted at N-l (compounds 5-7) was no more than 5% that of adenosine, and the effectiveness of these compounds relative to each other differed by only 2-fold. tivity; the potency of these four 2-substituted adenosines was between 2.8 and 27 times that of adenosine. However, 2-aminoadenosine had only 6% the activity of adenosine. Alkylation of the 6-amino group or its replacement by H, CH 3 , O, S, or Cl greatly reduced coronary vasoactivity. The low activity of inosine, 6-mercaptopurine riboside, and 6-chloropurine riboside may be due to the electron withdrawing effect of the C-6 substituents, for the 6-methoxy and 6-methylthiopurine ribosides were more active than the nonalkylated analogs. Of the three 8-substituted adenosines, only 8-iodoadenosine was active, but minimally so. The conventional explanation for the inactivity of 8-bromoadenosine in other systems, e.g., as a substrate for adenosine deaminase, is that the bulky bromine atom (Van der Waals radius 1.96 A) sterically hinders rotation about the glycosylic bond by impinging on C-2' and/or C-3' of the ribose, thus forcing the nucleoside into a syn conformation which is unfavorable for binding (Ikehara and Fukui, 1974) . This could explain the lack of coronary vasoactivity of 8-bromo-and 8-mercaptoadenosine (the Van der Waals radius of I is 2.15 A). Because the vasoactivity of 8-iodoadenosine could occur if the nucleoside were contaminated with only 0.1% adenosine, the hemodynamic studies were repeated after the nucleoside was recrystallized twice, but vasoactivity persisted. Thus, this exceptional result remains unexplained. Because 2-aminoadenosine is less active than adenosine, we tested a limited number of 2-aminopurine ribosides (compounds 25-27) to evaluate the possibility that a 2-amino group generally lowers vasoactivity. None of these nucleosides was very active; the lack of a consistent relationship between their activities and those of the 2-H analogs (compounds 13, 15, and 21) failed to support this hypothesis.
Although 6-(4-nitrobenzylthio) guanosine is listed in Table 1 under the 6-substituted, 2-aminopurine ribosides, it was studied for another reason. This nucleoside is a powerful inhibitor of nucleoside transport in erythrocytes (Paterson and Oliver, 1971 ) and also in canine heart, wherein the apparent K; of adenosine transport is 20 /IM (Olsson et al., 1972) . In this study it produced half-maximal coronary vasodilation at a concentration of 17 ftM, a value similar to that of the K, of adenosine transport inhibition, which suggests that its coronary vasodilation, and that of other nucleosides that inhibit adenosine transport , may result from the accumulation of adenosine rather than from a direct effect of the nucleoside on the adenosine receptor. However, this hypothesis is not supported when this comparison is extended to other nucleosides. Neither the actual EDso nor the rank order of potency as a coronary vasodilator correlated with the ability to inhibit adenosine transport (Table 2) .
Glycosylic Torsion Angle
Rotation of the purine base around the axis of the N-9 to C-l' glycosylic bond determines the shape of the adenosine molecule. The shape of the molecule is conventionally described by the glycosylic torsion angle, <>CN, which is defined as the angle made by the C-8 to N-9 and C-l' to 0-1' bonds viewed along the glycosylic bond from the C-l' to N-9 (Donohoe and Trueblood, 1960 ). The energy barriers to rotation are not large, but they are such that two conformations are somewhat favored, syn 4>CN -30 ± 45°) and anti (150 ± 45°). Nucleosides in solution are in a dynamic syn +± anti equilibrium; in the case of adenosine, the anti conformer is preferred 60:40 (Follman and Gremels, 1974) .
The coronary adenosine receptor will probably accept only those nucleoside molecules which happen to have a specific conformation. Consequently, the ratio of syn and anti conformers may be an index of the probability of binding. The inactivity of 8-substituted adenosines discussed above tends to exclude the syn conformer as the bound species. Direct evidence for binding of anti nucleosides was sought by evaluating cyclonucleosides fixed in this conformation by a covalent -O-or -S-bond between C-8 of the purine and either C-2', C-3' or C-5' of the sugar (compounds 29-33). However, all five of these cyclonucleosides were inactive.
Anomeric Configuration
In addition to rotation around the glycosylic bond, the shape of the adenosine molecule is deter- mined by the /S-anomeric configuration at C-l'; i.e., the base lies on the same side of the furanose ring as the exocyclic C-5' hydroxymethyl group and trans to the C-2' and C-3' hydroxyls. The a-anomer of adenosine (compound 43), in which the adenine base lies opposite its usual relationship to the ribofuranose ring, was completely inactive. This is probably the result of the loss of the contribution of binding to the purine domain of the receptor and also to the bulk of the adenine base sterically hindering the interaction of the C-2' and C-3' hydroxyls with the receptor.
Adenine Nucleosides
A series of adenine nucleosides differing from adenosine by virtue of single modifications of the sugar was used to probe the features of the ribose moiety that determine its contribution to binding. The ability of the hydroxyl groups to participate in hydrogen bonding makes it likely that binding to the receptor occurs through these functional groups. Isosteric substituents with different chemical reactivity will modify binding affinity in their own right, whereas those that are bulky could interfere additionally with the binding of neighboring functional groups. The three deoxyadenosines were less active than adenosine; 2'-deoxyadenosine was 70 times less potent, whereas 2'-and 5'-deoxyadenosine were, respectively, only 9 and 4.6 times less potent. Thus, binding seems most dependent on the 2'-hydroxyl but also to a lesser extent on the 3'-and 5'-hydroxyls. Both 2'-O-and 3-O-methyladenosine were less active than the corresponding deoxyribosides, suggesting limited bulk tolerance in the C-2'/ C-3' region of the receptor's ribose domain over and above the loss of the contribution each of these hydroxyls makes to binding affinity. The rank order of vasoactivity of these O-methyl ribosides is the reverse of the deoxyribosides, suggesting less bulk tolerance in the vicinity of C-3' than of C-2'. This hypothesis is supported by the fact that adenine psicofuranoside is vasoactive but adenine-a-L-lyxofuranoside is not. Psicofuranine may have less vasoactivity because its C-l' hydroxymethyl group sterically hinders the interaction of the C-3' hydroxyl with the receptor. Similarly, the inactivity of adenine-a-L-lyxofuranoside, which is the C-4' epimer of adenosine, may reflect steric hinderance exerted by the C-5' hydroxymethyl group on the interaction of the C-3' hydroxyl with the receptor. Adenine arabinofuranoside and adenine xylofuranoside, the C-2' and C-3' epimers of adenosine, were completely inactive. This cannot be due simply to the loss of the contribution of the epimeric hydroxyl group to binding, for one then would expect the same activities a3 the corresponding deoxynucleosides. Steric hi.derance is also an attractive explanation for the inactivity of these nucleosides, but it is uncertain whether this directly affects the fit of the nucleoside into the binding site or operates indirectly by, for example, the bulk of the epimeric hydroxyl hindering rotation of the base around the glycosylic bond to prevent a conformation favored for binding. The substantial activities of 3'-amino-3-deoxy-and 5'-amino-5'-deoxyadenosine indicate that an amino group can substitute effectively for a hydroxyl. Since amino groups can participate in hydrogen bonding, this supports the notion that these hydroxyls may interact with the receptor via hydrogen bonds.
All of the 5'-substituted ribosides were vasoactive except adenosine-5'-uronic acid and adenosine-5'-carboxaldehyde. The apparent inactivity of the carboxaldehyde may be misleading; this compound is only sparingly soluble in water. Under these conditions it was only possible to attain concentrations of ~90 fiM in coronary plasma water, well below the threshold concentration of many of the less active nucleosides. Interestingly, the (-) isomer of the 5'-deoxy-5'-S-ethylsulfoxyladenosine was active but the (+) diastereomer was not.
Although the duration of coronary vasoactivity was not examined systematically in this study, that of 5'-amino-5'-deoxyadenosine was exceptional. The maximum coronary vasodilation produced by infusing this nucleoside at the highest rate persisted for over 1 hour after analog administration was stopped. By comparison, the vasodilation produced by the other analogs usually dissipated in a few minutes.
Quantitative Structure-Activity Relationships
Surprisingly, the vasoactivity of adenosine and its analogs was completely unrelated to hydrophobicity. This was so whether one considered the entire ensemble as a whole or subgroups of closely related nucleosides, or whether one employed the 2-butanol:water distribution coefficient estimated experimentally or the hydrophobic parameter v taken from Hansch et al. (1973) .
The coronary vasoactivity of the 2-substituted adenosines correlates strongly with the a m substituent parameter, r = 0.88 ± 0.14, P < 0.001 (Fig. 5) . This analysis employed data on five nucleosides that were also studied by other investigators (Angus et al., 1971; Cobbin et al., 1974) . These independent estimates of log MPR are closely similar, indicating good agreement between laboratories. Factoring out the individual inductance and resonance contributions to a m revealed that log MPR correlated with the I substituent parameter almost as well as with a m ; r = 0.71 ± 0.12, 0.01 > P > 0.001.
The strong inductive effect of C-2 substituents and the general lack of a correlation between hydrophobicity and activity may find a common explanation in the chemistry of the pyrimidine moiety. This ring is aromatic but only to a very low degree; it does not participate in reactions characteristic of aromatic compounds such as nitrosation, sulfonation, or diazotization (Cavalieri and Bendich, 1950 ). Since aromaticity is slight, the lack of susceptibility to resonance effects is not unexpected. Similarly, since aromaticity and hydrophobicity tend to be covariant, the purine contribution to the hydrophobicity of adenosine is probably overwhelmed by the very hydrophilic sugar moiety. Although 2-chloroadenosine is to date the most potent of the 2-substituted adenosines, this analysis also predicts that other substituents such as --CN (o m = 0.56), -SO2CH3 (o m = 0.60), or -N(CH 3 ).T (a m = 0.88) should be even more active than -Cl (o m = 0.37). Attempts are under way in our laboratory to synthesize some of these nucleosides so that this hypothesis may be tested.
The vasoactivity of the 6-substituted ribosides correlated poorly with a m (r = 0.296, P > 0.1) or <J P (r = 0.120, P > 0.2) but correlated relatively well with the electrophilic substitution parameter a + (Brown and Okamoto, 1958) , r + 0.68 ± 0.25, 0.05 > P > 0.02, suggesting that the electron-withdrawing power of the C-6 substituent has an important influence on vasoactivity.
The probability that the lack of activity of the 8-substituted adenosines is due to steric factors was discussed above. Only three N-1-substituted adenosines were examined, too few to yield evaluable data.
The coronary vasoactivity of the 5'-substituted adenosines correlated with the inductive parameter, I, r = -0.78 ± 0.06, 0.01 > P > 0.001. Additionally, steric factors must be important, as 5'-(-)-s-ethylsulfoxyadenosine was vasoactive but its (+) diastereomer was not.
Discussion
Previous estimates of the concentration range over which adenosine exerts its coronary vasoactivity have ranged from a low value of 0.1-1 piM (Rubio et al., 1969) to a high value between 10 and 100 fiM (Moir and Downs, 1972) . In the last study cited, the maximum flow rates obtained during adenosine infusions were less than that at the peak of reactive hyperemia, which was interpreted as evidence that:
(1) adenosine is only a partial agonist and (2) adenosine cannot be responsible for the vasodilation of reactive hyperemia. These estimates are from openchest preparations and from different laboratories. The differences doubtless reflect undefined differences in experimental conditions and the variable degree of blunted coronary reactivity to be expected in open-chest preparations.
The present study provides an estimate of the vasoactivity of adenosine derived from an experimental preparation that is as nearly physiological as possible. This estimate lies in the range found by Rubio et al. (1969) , the ED50 being 0.57 fiM. Adenosine and those of its analogs that showed any coronary vasoactivity were full agonists, producing coronary vasodilation equal to that observed at the peak of reactive hyperemia. The range over which adenosine is vasoactive is similar to the range of adenosine concentrations estimated by direct analysis of heart muscle samples obtained under basal conditions and during reactive hyperemia (Olsson, 1970) , thus lending support to the idea that adenosine is an important determinant of coronary flow during physiological responses.
Although the vasodilatory potency of adenosine was less in the open-chest dogs than in conscious ones, the molar potency ratios of the eight analogs tested in both preparations were similar, suggesting that potency data from the two types of preparations are comparable. Moreover, it appears that estimates of molar potency ratios made in different laboratories or in the same laboratory at different times are closely similar (Angus et al., 1971; Cobbin et al., 1974) . This greatly expands the body of experimental data that can be used to determine structure-activity rules for these adenosine analogs and justifies the use of published data in some of the analyses made here.
Several of the analogs tested in this study are known to inhibit adenosine uptake, suggesting that their coronary vasoactivity may be due at least in part to raising adenosine concentrations in the cardiac interstitial space rather than entirely to a direct effect on coronary adenosine receptors. With the exception of 6-(4-nitrobenzylthio)guanosine, there was no correlation between the ED50 of coronary vasoactivity and the apparent Ki for inhibition of adenosine uptake (Table 2) . Because the coronary arteries of conscious animals are more sensitive to vasodilation by purine nucleosides than those of the open-chest preparation, comparisons of data on vasoactivity in the former with data on uptake inhibition in the latter are not strictly correct. However, the difference in the vasodilatory potency of adenosine between these preparations (less than 2-fold) is not enough to account for these large differences. Thus, the hemodynamic effects of most of these nucleosides appear to be due to direct interaction with the coronary arteries rather than to the accumulation of endogenous adenosine secondary to inhibition of its cellular uptake. The mechanism by which adenosine and its analogs cause coronary relaxation is unknown, and this study offers no insights into this question. However, this study does provide data on the relative potencies of various adenosine analogs in vitro in the event such a receptor is isolated.
The opportunity to study a larger number of chemically more diverse adenosine analogs and the application of quantitative techniques to define structure-activity relationships importantly extends earlier studies of the reasons for the vasoactivity of adenosine (Angus et al., 1971; Cobbin et al., 1974) . Collectively, these studies identify the size and hydrophobicity of the purine base, the amino group at C-6, a glycosylic torsion angle in the anti range and the ribo configuration of the C-2' and C-3' hydroxyl groups as major determinants of coronary vasoactivity. Unambiguous interpretations are not always possible since some of these factors, e.g., glycosylic torsion angle, the type of pseudorotation or puckering of the ribofuranose and, thus, the spatial orientation of the sugar hydroxyls, may be interdependent. The QSAR approach not only helped identify in some instances the underlying chemical features that may be responsible for biological activity, but it also afforded predictions with which to test additional hypotheses. We currently are attempting to synthesize some of the 2-substituted adenosines that QSAR predicts will be even more active than 2-chloroadenosine, the most active of these analogs studied to date.
The model for the coronary vascular smooth muscle adenosine receptor shown in Figure 4 consists of two binding domains, one that accommodates the adenine base and the other the ribose. The size of the base and the electronic effects of the C-2 and C-6 substituents appear to be the main determinants of binding to the purine domain, whereas the participation of all three sugar hydroxyls in hydrogen bonding and steric factors, particularly in the region of C-2' and C-3', seem to explain binding to the ribose domain. Although the experimental results do not define precisely the geometric relationship of the two domains, they suggest that the domains have a specific orientation which will accommodate only those nucleoside molecules that are in a particular conformation.
The inactivity of adenosines with bulky substituents at C-8 suggests that the glycosylic torsion angle of the bound species lies in the anti range, yet all of the nucleosides fixed in this conformation by virtue of a covalent bond between C-8 and a sugar carbon were inactive. There are at least three explanations for this result: (1) the most obvious explanation is that the glycosylic torsion angle required for binding may be different from those of these three types of nucleosides; (2) the formation of the purine-to-ribose bond may alter the structure of the sugar sufficiently to preclude binding; and (3) that one of these nucleosides does have the appropriate conformation for binding, but that receptor activation entails a subsequent conformational change in the receptor molecule which is prevented by the rigidity of the bound nucleoside molecule. The first possibility needs no further discussion. The second of these possible explanations is suggested by the fact that, in addition to fixing the glycosylic torsion angle, the covalent C-8-to-sugar bond of the 8,2'-and 8,3'-cyclonucleosides converts these sugars to the arabino and xylo configurations, respectively. Because both adenine arabinofuranoside and adenine xylofuranoside are inactive, it is not possible to decide whether the inactivity of these four cyclonucleosides is due to an unfavorable glycosylic torsion angle or to the altered configuration of the sugar. This ambiguity does not obtain in the case of the 8,5'-cyclonucleosides. Since the various 5'-deoxynucleosides are active and the purineto-ribose covalent bond does not change the ribo configuration of the sugar, the lack of vasoactivity probably is due to an unfavorable glycosylic torsion angle. The third hypothesis, that one of the cyclonucleosides can bind to the receptor but because of its rigidity the receptor cannot become activated via a secondary conformational change, suggests an indirect experimental test. If one of these cyclonucleosides can bind to the receptor, it should inhibit competitively the vasoactivity of adenosine. Unfortunately our limited supplies of these nucleosides did not permit such a test.
